Periostin and Childhood Craniopharyngioma: Unveiling the Connection
"Is Periostin a Marker for NAFLD Risk in Children with Craniopharyngioma? New research investigates the relationship between periostin levels and metabolic health in these patients."
Childhood-onset craniopharyngiomas (CP) are rare brain tumors that can lead to a host of long-term health issues. One particularly concerning complication is the development of non-alcoholic fatty liver disease (NAFLD), affecting roughly half of CP patients who also experience hypothalamic syndrome. NAFLD is characterized by excessive fat accumulation in the liver and can progress to more severe liver damage.
Scientists have been searching for reliable markers to identify individuals at higher risk of NAFLD so that interventions can be implemented early. One such marker is periostin, a protein involved in tissue repair and fibrosis. Periostin is highly expressed in the tumor environment of CP and has also been implicated in NAFLD. This raises an important question: could periostin levels in children with CP indicate their risk of developing NAFLD?
A recent study aimed to investigate whether periostin concentrations are elevated in the biological fluids of children with CP and if these levels correlate with indicators of liver health. The findings shed light on the complex relationship between CP, periostin, and NAFLD risk, offering potential insights into improved monitoring and care for these vulnerable patients.
Surgery, Imaging, and Treatment Tradeoffs
Craniopharyngioma treatment often requires surgical resection, with transcranial and transsphenoidal approaches described as conventional methods; a 2023 systematic review and meta-analysis set out to compare these with the more recently adopted supraorbital approach. The SIOPE recommendations call for emergency surgery to relieve pressure when hydrocephalus or threatened vision is present, using direct surgery or cyst-fluid aspiration, sometimes with an intracystic catheter for cystic lesions. For diagnostic workup, brain MRI with and without contrast is identified as the gold standard, while CT is optional and can show tumor calcifications. The complex location and potential effects on critical structures make management challenging.
Early Descriptions and Classification
Friedrich Albert von Zenker first described craniopharyngioma in 1857. Jakob Erdheim later characterized its histopathology and referred to these tumors as “hypophyseal duct tumours.” Erdheim proposed two types based on histological features: an aggressive type resembling jaw adamantinomas and a more benign type with papillary structures. The historical account also notes Babinski’s description of the patients’ clinical presentation.
Decoding Periostin: What the Study Revealed
The research team conducted a cross-sectional study involving 35 patients with sellar masses, including 32 with craniopharyngioma, recruited from the German Childhood Craniopharyngioma Registry. Additionally, the study included control groups consisting of children with growth hormone deficiency (GHD), those with decreased insulin-like growth factor-1 (IGF-1), and healthy children. Periostin levels were measured in serum, urine, and saliva samples.
- Periostin Levels: No significant differences were found in periostin concentrations in serum, urine, or saliva between CP patients and the control groups.
- Hypothalamic Involvement & Obesity: Hypothalamic involvement/lesions and the degree of obesity were not associated with elevated periostin concentrations.
- Liver Health: Similarly, liver enzyme levels did not correlate with periostin levels.
- IGF-1 Levels: Interestingly, a subgroup of patients with decreased IGF-1 levels showed elevated serum periostin concentrations compared to other groups.
Emerging Comorbidity Signatures and Clinical Reviews
An integrated microbiome and metabolome study reported increased Clostridium and up-regulated purine metabolism as potential signatures of craniopharyngioma-associated hypothalamic comorbidities; it also proposed that these changes, alongside redox imbalance, may contribute to their development and progression. A 2024 comprehensive review addresses clinical presentation, radiological findings, management, and future research directions. Separately, a review and meta-analysis reported that postoperative diabetes insipidus was highest after craniopharyngioma resection compared with other pituitary-region tumors.
Periostin Hypothesis and Management Challenges
A 2018 study framed periostin as a hypothesis for investigation: it noted high expression in craniopharyngioma-associated fibroblasts and its identification as a marker for non-alcoholic fatty liver disease (NAFLD), then asked whether periostin concentrations in biological fluids were elevated and associated with pathological hepatic parameters. The study’s rationale was that half of patients with hypothalamic syndrome develop NAFLD; the supplied material does not report its results, so it does not establish periostin as a clinical biomarker in this setting. More broadly, a 2020 review describes treatment as challenging despite the tumors’ benign histopathology, citing their complex central skull-base location, tumor biology, and difficult treatment decisions.
Periostin Measurement and Proton–Photon Evidence
A study of children with mild-to-moderate asthma measured periostin in non-concentrated exhaled breath condensate (EBC) and serum by ELISA in 23 children with asthma and 23 healthy controls. For craniopharyngioma, a 2024 systematic review and meta-analysis comparing proton and photon radiotherapy reported comparable event-free survival and endocrine dysfunction, while noting that the cost difference between the options is substantial. The review states that larger studies are needed to confirm the survival finding and assess long-term toxicity differences. The supplied materials do not provide a direct comparison of periostin results across the asthma and craniopharyngioma populations.
The Implications: Why This Research Matters
This study provides valuable insights into the complex relationship between periostin and metabolic health in children with craniopharyngioma. Although periostin doesn't appear to be a reliable marker for NAFLD risk in this population, the research highlights the importance of continued investigation into the factors that contribute to NAFLD development in CP patients.
Periostin as a Research Question
Periostin expression has been reported as increased in fibroblasts associated with adamantinomatous craniopharyngioma, and periostin has also been identified as a marker for NAFLD. The study rationale links these observations to childhood-onset craniopharyngioma with hypothalamic involvement, noting that half of such patients develop NAFLD. The investigators hypothesized that periostin concentrations in biological fluids might be elevated and associated with pathological hepatic parameters. These points describe the study’s premise, not evidence in the supplied material that periostin can predict liver disease in these patients.
Research on Adult-Onset Disease
A research topic titled “Advances and Challenges in Adult-Onset Craniopharyngiomas” brings together original articles, a comprehensive review, and illustrative clinical cases. Its stated focus is innovative research into adult-onset craniopharyngiomas. The supplied description does not give further findings or specify how those adult-focused materials apply to childhood disease.
Cases and Follow-Up in Clinical Reports
A case-series source describes patients treated for craniopharyngioma between January 2014 and January 2018 and says cases were followed for three and six months after treatment. A related report describes seven surgically treated cases and discusses the technical importance of EDATA for radical removal. A 2024 case report presents a boy with a periventricular-region tumor and analyzes his medical records alongside the current literature. These reports offer individual and small-series perspectives; the supplied snippets do not provide detailed outcomes for the patients.
The unexpected finding of elevated periostin levels in CP patients with low IGF-1 opens up new avenues for research. Future studies could explore the role of periostin in IGF-1 signaling and its potential connection to metabolic dysfunction in this specific subgroup.
Ultimately, a deeper understanding of the metabolic challenges faced by children with craniopharyngioma is crucial for developing targeted strategies to prevent and manage complications like NAFLD, improving their long-term health and quality of life.